BioCryst (BCRX) has transitioned from a development-stage biotech into a profitable, commercial rare-disease company anchored by ORLADEYO, the first and only once-daily oral prophylactic for hereditary angioedema (HAE). In FY2025, ORLADEYO generated ~$601.8M net revenue (+38% y/y) and enabled BioCryst’s first full year of profitability, with record total revenue (~$874.8M) and GAAP operating profit (~$341M). A pivotal strategic move was divesting European ORLADEYO operations to Neopharmed, delivering ~$243.3M in upfront licensing revenue and sharpening focus on the U.S., expected to contribute >90% of 2026 revenue. The franchise is expanding with FDA approval of pediatric ORLADEYO oral pellets (ages 2 to <12), increasing lifetime patient value and reinforcing the “convenience-first” positioning versus injectable prophylaxis. To broaden beyond oral convenience and compete on peak efficacy/low burden, BioCryst acquired Astria and added navenibart, a Phase 3 long-acting antibody with potential 3–6 month dosing. The company now aims to own both the oral and potentially best-in-class long-interval injectable segments in HAE while using improving economics (including entry into a zero-royalty tier) to self-fund pipeline development.

BioCryst Pharmaceuticals Inc (BCRX) Investment Analysis

1. Executive Summary

BioCryst Pharmaceuticals Inc. (BCRX) is a commercial-stage biotechnology company that has transitioned from a research-focused organization into a specialized rare disease powerhouse with a sustainable revenue model. The company specializes in the discovery and commercialization of oral small-molecule and protein therapeutics for orphan diseases, with a primary strategic focus on Hereditary Angioedema (HAE). BioCryst generates revenue through the direct commercial sale of its flagship product, ORLADEYO® (berotralstat), as well as through strategic licensing agreements, royalties, and the supply of its legacy antiviral product, RAPIVAB® (peramivir injection), to government agencies.[1, 2]

The company’s operations are currently defined by the robust performance of ORLADEYO, which stands as the first and only once-daily, oral prophylactic treatment for HAE.[3, 4] In the fiscal year 2025, BioCryst achieved a transformational milestone by reporting its first full year of profitability, driven by $601.8 million in total ORLADEYO net revenue.[1, 5] This financial pivot was facilitated by a strategic decision to divest its European ORLADEYO operations to Neopharmed Gentili S.p.A. in late 2025, a move that provided a significant capital infusion of $243.3 million in upfront licensing revenue and streamlined the company’s focus on the high-value United States market.[1, 5]

BioCryst’s core products and services center on its HAE franchise, which now includes ORLADEYO capsules for adults and adolescents (12+), newly approved oral pellets for pediatric patients (ages 2 to <12), and the late-stage pipeline asset navenibart (formerly STAR-0215).[1, 6, 7] Its primary customer types are specialized physicians—specifically immunologists and allergists—and the patients they treat who suffer from recurrent, life-threatening swelling episodes. The most important end market for the company is the United States, which is expected to generate over 90% of the 2026 revenue guidance.[8, 9] Customers choose BioCryst’s oral therapy over traditional alternatives, such as Takeda’s Takhzyro or CSL Behring’s Haegarda, because it offers the convenience of a pill versus the significant treatment burden associated with frequent subcutaneous injections or intravenous infusions.[6, 10]

Strategically, BioCryst is moving toward a multi-asset platform. The January 2026 acquisition of Astria Therapeutics integrated navenibart into the portfolio, a monoclonal antibody with the potential to provide high-efficacy HAE protection with dosing only every three or six months.[11, 12] By offering both the leading oral therapy and a potential best-in-class injectable, BioCryst aims to dominate the HAE prophylaxis segment while leveraging its established commercial infrastructure to drive operating leverage and long-term shareholder value.[13, 14]

2. Business Drivers & Strategic Overview

Product and Service Detail: The HAE Franchise

BioCryst’s primary value driver is the inhibition of plasma kallikrein, a critical enzyme in the inflammatory cascade that, when unregulated, leads to the overproduction of bradykinin and the subsequent swelling associated with HAE.[7, 15] The company’s lead product, ORLADEYO (berotralstat), is an oral small molecule that inhibits plasma kallikrein with high specificity. It is currently sold in 110 mg and 150 mg once-daily capsules for patients aged 12 and older.[4, 16]

In December 2025, the company received FDA approval for a new oral pellet formulation, expanding the ORLADEYO label to include pediatric patients aged 2 to <12.[1, 7] This is a critical strategic development because it allows BioCryst to capture patients much earlier in their disease journey. Pediatric HAE is notoriously difficult to manage with injectables, and providing an oral option for young children addresses a severe unmet need for both patients and caregivers.[4, 6]

The secondary driver of the company’s strategic outlook is navenibart, a monoclonal antibody currently in Phase 3 clinical development (the ALPHA-ORBIT trial).[11, 17] Navenibart is designed for ultra-long-acting prophylaxis. Clinical data from the Phase 1b/2 ALPHA-STAR trial demonstrated that navenibart can achieve mean HAE attack rate reductions of 92% and 90% with quarterly and six-month dosing regimens, respectively.[11, 18] This asset represents the "injectable wing" of BioCryst’s strategy, aimed at the approximately 5,000 U.S. patients who currently use injectable prophylaxis but desire a lower treatment burden.[13]

Beyond HAE, BioCryst is advancing BCX17725, a protein therapeutic targeting Kallikrein-related peptidase 5 (KLK5) for the treatment of Netherton Syndrome, a rare and severe genetic skin disease.[15, 19] The company is currently conducting a Phase 1 study, with Part 4 data in Netherton patients expected by year-end 2026.[11] This program underscores BioCryst's ability to apply its enzymology expertise to diverse rare disease states.

Moat Analysis: Barriers to Entry and Durability

BioCryst’s competitive moat is multi-layered, consisting of intellectual property, high switching costs, and unique economic tiers within its royalty structures.

• Intellectual Property (IP): ORLADEYO is protected by an extensive patent estate. While certain patents related to crystalline forms expire in 2039, the core composition-of-matter patents extend through 2035.[20, 21] Despite an ANDA challenge from Annora/Hetero in early 2025, which targeted the 2039 patents, the 2035 patents remain unchallenged, providing a clear decade of exclusivity.[22] Navenibart additionally has a patent runway extending into 2040.[23, 24]
• Switching Costs: In rare diseases like HAE, the "physician-patient-payer" relationship creates a powerful inertia. Once a patient is stabilized on a daily oral pill and avoids life-threatening attacks, the perceived risk of switching to a new modality is high. BioCryst reports that nearly 50% of all patients who have ever tried ORLADEYO in the U.S. remain on the therapy years later, suggesting deep clinical entrenchment.[6]
• Royalty Inflection: A unique economic moat for BioCryst is the "zero-royalty tier." Having surpassed $550 million in annual ORLADEYO revenue in 2025, the company has reached a threshold where its royalty obligations on incremental sales are eliminated.[11] This increases the contribution margin to over 80%, providing massive cash flow that can be reinvested into R&D without the need for further equity dilution.[11]
• Distribution and Patient Services: BioCryst has built a bespoke commercial infrastructure, including "BioCryst Connect," a patient service platform that manages insurance reauthorizations, co-pay assistance, and specialty pharmacy delivery.[13, 14] This high-touch model creates an ecosystem that is difficult for generic or new entrants to replicate.

TAM / Market Opportunity Analysis

The global HAE market is robust and growing, driven by improved diagnosis rates and the shift toward long-term prophylaxis. The market size is estimated to be $3.44 billion in 2026 and is projected to reach $6.61 billion by 2033, a CAGR of 9.8%.[25] Other estimates for the therapeutics segment specifically project a value of $6.83 billion by 2026, growing to $14.69 billion by 2031.[26]

Market Metric	Value	Source
2026 Estimated HAE Market Size	$3.44 Billion	[25]
2031 Projected HAE Market Size	$14.69 Billion	[26]
ORLADEYO Peak Revenue Target	$1.0 Billion (by 2029)	[11]
Netherton Syndrome Market (2035)	$79.1 Million	[27]

BioCryst’s goal of $1 billion in peak ORLADEYO revenue implies capturing roughly 15-20% of the total global HAE market.[11] For Netherton Syndrome, while the current market is small ($23.8M in 2024), the lack of targeted therapies means the launch of BCX17725 could significantly expand the diagnosed patient pool, much like the introduction of targeted biologics did for atopic dermatitis.[11, 27]

Competitive Landscape

BioCryst operates in a highly competitive segment dominated by large pharmaceutical players and innovative biotechs.

• Takeda (Takhzyro): The current market leader. Takhzyro (lanadelumab) is a subcutaneous injection given every two weeks (or monthly after stabilization).[28, 29] It generated $1.2 billion in sales recently.[10] While highly effective (up to 87% attack reduction), it remains an injectable.
• CSL Behring (Andembry): Approved in June 2025, Andembry (garadacimab) is a Factor XIIa inhibitor given monthly.[30, 31] It offers 89% attack reduction and represents a major threat to Takhzyro and potentially ORLADEYO.[32, 33]
• Ionis Pharmaceuticals (Dawnztera): Approved in August 2025, donidalorsen (Dawnztera) is an RNA-targeted therapy given every 4 or 8 weeks.[34] In a switch study, 84% of patients preferred Dawnztera over their prior prophylaxis, which included ORLADEYO.[34]
• KalVista Pharmaceuticals: Developing sebetralstat (EKTERLY), an oral on-demand treatment that could compete for patient mindshare, though it targets acute attacks rather than prophylaxis.[35]

BioCryst is currently holding ground by dominating the "oral" preference segment. While injectables like Andembry and Dawnztera offer higher absolute efficacy, ORLADEYO's "convenience" value proposition remains strong for the ~40% of patients who are averse to needles.[6] However, the acquisition of navenibart is a defensive and offensive move, ensuring that BioCryst can compete for the "efficacy-first" patient who is willing to inject but wants the longest possible dosing interval (3-6 months).[13]

3. Financial Performance & Valuation

Analysis of Latest Results

BioCryst reported its full-year 2025 and fourth-quarter 2025 financial results on February 26, 2026.[5, 36] The 2025 fiscal year was the most successful in the company's history, marked by record total revenue of $874.8 million and a GAAP operating profit of $341.0 million.[1]

Revenue Breakdown (FY 2025):
* ORLADEYO Net Revenue: $601.8 million (up 38% y-o-y).[1]
* European License Revenue: $243.3 million (one-time gain from sale to Neopharmed).[1, 5]
* Non-GAAP ORLADEYO Revenue (Adjusted for Europe): $563 million, reflecting a 43% comparable growth.[37]

In the fourth quarter of 2025, BioCryst posted an EPS of $0.06, which missed the consensus analyst estimate of $0.07.[38] Revenue for the quarter was $151 million, beating the preliminary guidance range provided in January 2026.[37, 39] The company’s cash, cash equivalents, and investments totaled $337.5 million at year-end.[1]

Guidance and Management Commentary

During the February 26 conference call, management maintained its 2026 outlook:
* ORLADEYO Net Revenue Guidance: $625 million to $645 million (13% growth over 2025 adjusted base).[1, 8]
* Total Revenue Guidance: $635 million to $660 million.[1]
* Non-GAAP Operating Expense Guidance: $450 million to $470 million. This includes a $70M-$80M increase specifically to support the integration of Astria Therapeutics and the Phase 3 ALPHA-ORBIT trial for navenibart.[37, 39]

CFO Babar Ghias noted that R&D expenses would rise in 2026 due to these BLA-enabling activities, but emphasized that the company expects to remain non-GAAP profitable throughout 2026.[1, 8] President Charlie Gayer warned investors about Q1 seasonality, noting that Q1 2026 revenue would likely be "slightly down versus Q4" due to the insurance reauthorization cycle, a standard trend in the specialty pharmacy market.[8]

Market Reaction and Valuation Drivers

The stock price reaction to the February earnings was a modest decline of approximately 2.4% to $9.45.[9] This muted reaction suggests that the market had already priced in the strong 2025 performance following the preliminary update in January. However, analyst sentiment remains constructive, with a median price target of $21.40 representing significant potential upside.[40]

Financial Driver	5-Year Assumption	Rationale
ORLADEYO Sales Growth (CAGR)	~15%	Expansion into pediatrics and 150 net new patients/year [11]
Paid Rate Improvement	To 85% by 2029	Optimization of BioCryst Connect platform [11, 23]
Operating Margins (Non-GAAP)	~25-30%	Scaling into zero-royalty tier after $550M rev [11]
Share Count	265M (Diluted)	Includes 37.3M shares for Astria and employee grants [14, 41]

The valuation is heavily dependent on the "terminal value" of the HAE franchise. With IP extending to 2035/2040 and a pipeline (navenibart) that could double the total addressable market, BioCryst is currently valued more like a maturing specialty pharma than a high-risk biotech. Its Price/Sales ratio of 2.71x is significantly lower than the industry average for companies with 40%+ growth rates, suggesting the market is still discounting the durability of the oral HAE segment.[42, 43]

4. Risk Assessment & Macroeconomic Considerations

Company-Specific Execution Risks

• Management Transition: The retirement of long-time CEO Jon Stonehouse at the end of 2025 and the promotion of Charlie Gayer creates a leadership transition risk.[44, 45] While Gayer is deeply familiar with the commercial strategy, executing a multi-asset launch (ORLADEYO pediatric + navenibart preparation) is a complex organizational challenge.
• Clinical/Regulatory Setbacks: The navenibart Phase 3 ALPHA-ORBIT trial is currently enrolling.[7, 17] Any failure to replicate the high attack reduction seen in Phase 2, or any safety signal in the larger patient pool, would significantly impair the company's 2030 growth trajectory.[7, 11]
• Early Warning Sign: A "miss" in the net new patient addition numbers for two consecutive quarters would be the first indicator that the HAE market is maturing faster than management anticipates.[46]

Competitive and Industry Structure Risks

• Efficacy Erosion: If new injectables like Dawnztera (Ionis) and Andembry (CSL) achieve attack-free rates significantly higher than ORLADEYO (e.g., >95% vs ~60%), even the most needle-averse patients may be persuaded to switch for better disease control.[28, 34]
• Pricing Pressure: As more competitors enter the HAE space (Takeda, CSL, Ionis, KalVista), payers may begin to demand higher rebates or implement "step-therapy" requirements, favoring lower-cost options and squeezing margins.[9, 25]

Regulatory and Legal Risks

• Patent Litigation: The Annora ANDA challenge is a "what could go wrong" scenario. While BioCryst has sued to defend its 2039 patents, a loss could bring forward the "patent cliff" from 2035 to 2029.[16, 22]
• Medicare IRA Impact: The Inflation Reduction Act’s redesign of Medicare Part D (effective 2025-2026) caps patient out-of-pocket costs at $2,000.[47, 48] While this may increase volume by making the drug more accessible, the manufacturer is now responsible for a larger "discount" (20%) in the catastrophic phase, potentially impacting net realized price.[48, 49]

Balance Sheet and Capital Allocation Risks

• Blackstone Debt: The $400 million senior credit facility is a double-edged sword.[14, 50]
  • Structure: Interest is 3-month SOFR + 4.5%.[50]
  • Sensitivity: If interest rates remain elevated (SOFR > 4%), the annual interest burden could exceed $35 million, consuming a large portion of operating profits.[50, 51]
  • Early Warning Sign: Any breach of covenants or the need to utilize the "PIK" (Payment-In-Kind) interest option would signal cash flow distress.[50]

Macroeconomic Sensitivities

• Interest Rates: As a biotech with substantial debt, BioCryst is sensitive to the cost of capital. High rates make refinancing difficult and lower the present value of future pipeline cash flows.[52]
• Geopolitical Instability: Recent volatility in BioCryst’s stock has been linked to broader market "risk-off" sentiment stemming from conflicts in the Middle East and surging oil prices.[53] While not directly related to drug sales, such macro shocks can cause institutional investors to exit mid-cap biotech positions, creating downward pressure regardless of fundamentals.

5. 5-Year Scenario Analysis

Base Case Scenario (55% Probability)

The Base Case assumes ORLADEYO continues its current trajectory, reaching $1 billion in peak sales by 2029.[11] Navenibart successfully completes Phase 3 in early 2027 and launches in 2028, capturing a meaningful share of the injectable market.[13, 17]
* Revenue Year 5: $1.45 billion.
* Operating Margin: 28% (Scaling with zero-royalty tier).
* Share Count: 268 million (Assuming routine equity compensation).
* EPS Projection: $1.22.
* Exit Multiple: 18x P/E.
* Projected Share Price: $21.96.

High Case Scenario (20% Probability)

In the High Case, ORLADEYO outperforms, reaching $1.2 billion by 2030, aided by rapid international uptake and pediatric market dominance. Navenibart establishes itself as the "Gold Standard" injectable with dosing every six months, achieving $500 million in sales by year 5. BCX17725 receives FDA approval for Netherton Syndrome, adding a new $100M+ revenue stream.
* Revenue Year 5: $1.90 billion.
* Operating Margin: 38% (High operating leverage).
* Share Count: 260 million (Company begins share repurchases).
* EPS Projection: $2.35.
* Exit Multiple: 22x P/E.
* Projected Share Price: $51.70.

Low Case Scenario (25% Probability)

The Low Case reflects a scenario where competitive pressure from Ionis and CSL significantly erodes ORLADEYO’s market share.[46] Sales peak at $650 million and begin to decline as the market shifts entirely to long-acting injectables. Navenibart Phase 3 results are "me-too" data, leading to a slow launch in a crowded market.
* Revenue Year 5: $800 million.
* Operating Margin: 12% (High fixed costs and debt service).
* Share Count: 290 million (Further dilution to fund operations).
* EPS Projection: $0.28.
* Exit Multiple: 12x P/E.
* Projected Share Price: $3.36.

5-Year Scenario Summary Table

Scenario	Rev (Year 5)	Margin / EPS	Valuation Multiple	Implied Price	5-Year Return	Probability
High	$1.90B	38% / $2.35	22x P/E	$51.70	+445%	20%
Base	$1.45B	28% / $1.22	18x P/E	$21.96	+132%	55%
Low	$0.80B	12% / $0.28	12x P/E	$3.36	-64%	25%

Weighted Probability Target: $23.26

BLOCKBUSTER GROWTH IMMINENT

6. Qualitative Scorecard

Category	Score (1-10)	Narrative
Management Alignment	9	CEO Charlie Gayer and founder Jon Stonehouse maintain significant holdings (1.32M and 952k shares respectively).[54] Insider activity shows strategic adds, such as Sandeep Menon's 646k share inducement grant.[54, 55]
Revenue Quality	9	High-margin orphan drug sales. The zero-royalty tier above $550M makes ORLADEYO's cash flow exceptionally high quality.[11]
Market Position	7	BioCryst is the "Oral King" of HAE but is currently in a defensive crouch against new, highly effective injectables from Ionis and CSL.[25, 28]
Growth Outlook	8	Doubling down on HAE with both oral and injectable options. The trajectory toward $1.8B+ by 2033 is well-supported by current pipeline timelines.[11]
Financial Health	7	Record 2025 profitability is a massive plus.[1, 5] However, the $400M Blackstone debt at floating rates is an expensive burden that requires careful monitoring.[50]
Business Viability	9	HAE is a chronic condition with life-long patients. The IP runway to 2035/2040 provides high durability against generic threats.[20, 21]
Capital Allocation	7	The $700M Astria deal was a bold, necessary move to protect the HAE franchise, though it added leverage to the balance sheet.[13, 14]
Analyst Sentiment	9	Consensus is a "Strong Buy" (10 of 10 in some polls) with an average target price implying >100% upside.[40, 56]
Profitability	8	Achieving GAAP profitability in 2025 marks the transition to a self-sustaining entity.[1] Non-GAAP profits are projected to persist.[37]
Track Record	6	Historically characterized by high volatility and clinical setbacks (Factor D), but the 2024-2025 era shows a "New BioCryst" with commercial discipline.[1, 5]

Blended Score: 7.9 / 10

DURABLE ORPHAN POWERHOUSE

7. Conclusion & Investment Thesis

BioCryst Pharmaceuticals has successfully navigated the most challenging phase of the biotech lifecycle, transitioning from a loss-making R&D firm to a profitable, commercial entity. The investment thesis is predicated on the continued expansion of the ORLADEYO franchise and the successful launch of navenibart as a long-acting injectable.

The company has successfully carved out a "convenience-first" niche in the HAE market, a segment that is largely protected from new injectable competition due to patient aversion to needles. With the recent pediatric approval, BioCryst has extended its market leadership to a new, younger demographic, ensuring a pipeline of long-term "life-time" patients. The zero-royalty inflection point reached in 2025 is a critical financial driver, as it allows the company to fund its Phase 3 programs (navenibart and BCX17725) entirely from internal cash flow, removing the "dilution overhang" that often plagues biotech stocks.

While risks remain—specifically the potential for competitive "efficacy erosion" and the burden of floating-rate debt—the current valuation of 2.7x Sales appears to significantly underestimate the compounding value of a profitable orphan drug platform. The upcoming catalysts in 2026, including Netherton Syndrome data and sustained pediatric growth, provide multiple pathways for share price appreciation.

UNDERVALUED RARE LEADER

8. Technical Analysis, Price Action & Short-Term Outlook

BioCryst (BCRX) is currently trading at $9.67, firmly above its 200-day moving average of $7.87, signaling a long-term bullish trend.[53, 57] The stock surged 11% in early 2026 following positive pipeline updates but has recently consolidated amid a broader healthcare sector pullback.[53, 58] Technical indicators such as RSI (40.5) and MACD suggest a neutral-to-oversold condition in the short term, with strong support near $9.00.[59] The short-term outlook is cautiously optimistic as investors anticipate Q1 results on May 6, 2026, with technical levels suggesting potential for a re-test of the 52-week high ($11.31) if guidance is maintained or raised.[59, 60]

BULLISH TREND RETAINED

---

1. BioCryst Reports Full Year 2025 Financial Results and Provides Business Update, https://ir.biocryst.com/news-releases/news-release-details/biocryst-reports-full-year-2025-financial-results-and-provides
2. BioCryst (BCRX) expands HAE franchise and rare-disease pipeline - Stock Titan, https://www.stocktitan.net/sec-filings/BCRX/10-k-biocryst-pharmaceuticals-inc-files-annual-report-8e5a47fc1037.html
3. BioCryst to Report First Quarter 2026 Financial Results on May 6, https://ir.biocryst.com/news-releases/news-release-details/biocryst-report-first-quarter-2026-financial-results-may-6
4. BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting, https://ir.biocryst.com/news-releases/news-release-details/biocryst-present-new-hae-data-orladeyor-berotralstat-and
5. BioCryst Reports Full Year 2025 Financial Results and Provides Business Update, https://www.stocktitan.net/news/BCRX/bio-cryst-reports-full-year-2025-financial-results-and-provides-bw4l20ok8fbb.html
6. BCRX - BioCryst Pharmaceuticals Inc Earnings Call Transcripts - Morningstar, https://www.morningstar.com/stocks/xnas/bcrx/earnings-transcript
7. Updates provided on berotralstat and navenibart - HAE International (HAEi), https://haei.org/updates-provided-on-berotralstat-and-navenibart/
8. BioCryst outlines $625M–$645M 2026 ORLADEYO revenue target as HAE pipeline advances (NASDAQ:BCRX) | Seeking Alpha, https://seekingalpha.com/news/4558117-biocryst-outlines-625m-645m-2026-orladeyo-revenue-target-as-hae-pipeline-advances
9. Earnings call transcript: BioCryst Q4 2025 shows strong growth, stock dips - Investing.com, https://www.investing.com/news/transcripts/earnings-call-transcript-biocryst-q4-2025-shows-strong-growth-stock-dips-93CH-4586344
10. With FDA nod for HAE drug Andembry, CSL set to compete with Takeda's Takhzyro - Fierce Pharma, https://www.fiercepharma.com/pharma/fda-nod-hae-treatment-andembry-csl-set-compete-takedas-blockbuster-takhzyro
11. BioCryst 2025 slides: path to $1B revenue, Navenibart expands portfolio By Investing.com, https://www.investing.com/news/company-news/biocryst-2025-slides-path-to-1b-revenue-navenibart-expands-portfolio-93CH-4586347
12. Astria Therapeutics (ATXS) completes BioCryst merger with $400M term loan - Stock Titan, https://www.stocktitan.net/sec-filings/ATXS/8-k-astria-therapeutics-inc-reports-material-event-22ea5ab4a87a.html
13. BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile, https://ir.biocryst.com/news-releases/news-release-details/biocryst-acquire-astria-therapeutics-strengthening-presence-hae
14. BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema, https://ir.biocryst.com/news-releases/news-release-details/biocryst-completes-acquisition-astria-therapeutics-expanding
15. Product Pipeline | BioCryst®, https://www.biocryst.com/science/pipeline/
16. When will the ORLADEYO patents expire, and when will ORLADEYO go generic? - DrugPatentWatch, https://www.drugpatentwatch.com/p/tradename/ORLADEYO
17. Biocryst to present new Orladeyo, navenibart data at AAAAI meeting - Angioedema News, https://angioedemanews.com/news/biocryst-slated-present-orladeyo-navenibart-data-aaaai/
18. An Open-Label Phase 1b/2 Trial of Navenibart, a Long-Acting Plasma Kallikrein Inhibitor for Hereditary Angioedema - PubMed, https://pubmed.ncbi.nlm.nih.gov/41794053/
19. Netherton Syndrome Market Size, Share & Forecast, 2026-2033, https://www.coherentmarketinsights.com/industry-reports/netherton-syndrome-market
20. Generic Orladeyo Availability & Release Date - Drugs.com, https://www.drugs.com/availability/generic-orladeyo.html
21. Form 8-K for Biocryst Pharmaceuticals INC filed 02/24/2025, https://ir.biocryst.com/static-files/ca3ddd70-604d-4c83-9870-4827ca3741fc
22. SEC Filing - BioCryst Pharmaceuticals, Inc., https://ir.biocryst.com/node/26726/html
23. BioCryst JPM Healthcare Conference 2026 Presentation, https://ir.biocryst.com/static-files/5a7fc8c1-15d9-4c5b-a3db-b0f6e07fd632
24. Full Year 2025 Results Call - BioCryst Pharmaceuticals, Inc., https://ir.biocryst.com/static-files/4fe82d5a-8c02-4760-a8ad-bd1ce766e85b
25. Hereditary Angioedema Market Size and Forecast, 2026-2033 - Coherent Market Insights, https://www.coherentmarketinsights.com/market-insight/hereditary-angioedema-market-1292
26. Hereditary Angioedema Therapeutics Market Size, Share & Industry Outlook- 2031, https://www.mordorintelligence.com/industry-reports/hereditary-angioedema-therapeutics-market
27. Netherton Syndrome Market Size 2025-2035 - IMARC Group, https://www.imarcgroup.com/netherton-syndrome-market
28. CSL, seeking to stall Takeda drug, links antibody to rare disease benefits and plans global filings - Fierce Biotech, https://www.fiercebiotech.com/biotech/csl-seeking-stall-fast-growing-takeda-drug-links-antibody-rare-disease-benefits-and-plans
29. Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12308543/
30. Andembry (garadacimab-gxii) FDA Approval History - Drugs.com, https://www.drugs.com/history/andembry.html
31. U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start - Jun 16, 2025 - Global Newsroom | CSL, https://newsroom.csl.com/2025-06-16-U-S-Food-and-Drug-Administration-Approves-CSLs-ANDEMBRY-R-garadacimab-gxii-,-the-Only-Prophylactic-Hereditary-Angioedema-HAE-Treatment-Targeting-Factor-XIIa-with-Once-Monthly-Dosing-for-All-Patients-From-the-Start
32. FDA Approves Garadacimab-gxii in Hereditary Angioedema - AJMC, https://www.ajmc.com/view/fda-approves-garadacimab-in-hereditary-angioedema
33. Garadacimab-gxii Receives FDA Approval for Hereditary Angioedema Treatment, https://www.pharmacytimes.com/view/garadacimab-gxii-receives-fda-approval-for-hereditary-angioedema-treatment
34. FDA Approves Donidalorsen as First RNA-Targeted Prophylactic Treatment for Hereditary Angioedema | Pharmacy Times, https://www.pharmacytimes.com/view/fda-approves-donidalorsen-as-first-rna-targeted-prophylactic-treatment-for-hereditary-angioedema
35. KLKB1 Inhibitors Market to Reach New Heights by 2034 Owing to the Launch of Novel Therapies | DelveInsight, https://www.prnewswire.com/news-releases/klkb1-inhibitors-market-to-reach-new-heights-by-2034-owing-to-the-launch-of-novel-therapies--delveinsight-302619660.html
36. 0001628280-26-012240 | 10-K | BioCryst Pharmaceuticals, Inc., https://ir.biocryst.com/sec-filings/sec-filing/10-k/0001628280-26-012240
37. BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range, https://ir.biocryst.com/news-releases/news-release-details/biocryst-announces-preliminary-full-year-2025-orladeyor
38. BioCryst Pharmaceuticals (BCRX) Earnings: Latest Report, Earnings Call & Financials, https://public.com/stocks/bcrx/earnings
39. Form 8-K for Biocryst Pharmaceuticals INC filed 01/12/2026, https://ir.biocryst.com/static-files/a7dfe18b-cfc0-4f98-af3a-ebc336728de8
40. BioCryst (BCRX) Stock Forecast & Price Target - Investing.com, https://www.investing.com/equities/biocryst-pharmaceuticals-consensus-estimates
41. BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Stock Titan, https://www.stocktitan.net/news/BCRX/bio-cryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-o827qf4aik42.html
42. Top BioCryst Pharmaceuticals (BCRX) Competitors 2026 - MarketBeat, https://www.marketbeat.com/stocks/NASDAQ/BCRX/competitors-and-alternatives/
43. BioCryst Pharmaceuticals, Inc. (BCRX) Stock Price, Quote, News & Analysis | Seeking Alpha, https://seekingalpha.com/symbol/BCRX
44. BCRX CEO transition: Charlie Gayer to succeed Jon Stonehouse in 2026 - Stock Titan, https://www.stocktitan.net/sec-filings/BCRX/8-k-bio-cryst-pharmaceuticals-inc-reports-material-event-9003bd24c67c.html
45. Form 8-K - SEC.gov, https://www.sec.gov/Archives/edgar/data/882796/000117184325004869/f8k_073125.htm
46. BioCryst Pharmaceuticals (BCRX) Stock Forecast: Analyst Ratings, Predictions & Price Target 2026 - Public Investing, https://public.com/stocks/bcrx/forecast-price-target
47. 3 Big Medicare Prescription Drug Changes Coming in 2026 - AARP, https://www.aarp.org/medicare/future-medicare-drug-payment-changes-2026/
48. What's Killing Part D: The Policy Failures of the IRA - Paragon Health Institute, https://paragoninstitute.org/paragon-prognosis/whats-killing-part-d-the-policy-failures-of-the-ira/
49. Estimated discounts generated by Medicare drug negotiation in 2026 - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC10397328/
50. Form 8-K for Biocryst Pharmaceuticals INC filed 01/23/2026, https://ir.biocryst.com/static-files/d8f1eda5-2b79-4cc8-88be-179b3a9b91e3
51. Secured Overnight Financing Rate (SOFR) | FRED | St. Louis Fed, https://fred.stlouisfed.org/series/SOFR
52. XBI vs. IBB: The Biotech ETF Showdown That Analysts Say Has a Clear Winner in 2026 - 24/7 Wall St., https://247wallst.com/investing/2026/04/07/xbi-vs-ibb-the-biotech-etf-showdown-that-analysts-say-has-a-clear-winner-in-2026/
53. BioCryst Pharmaceuticals, Inc. Stock Price: Quote, Forecast, Splits & News (BCRX), https://www.perplexity.ai/finance/BCRX
54. Biocryst Pharmaceuticals Inc (BCRX) Insider Ownership - Business Quant, https://businessquant.com/stocks/bcrx/insiders/
55. BioCryst (BCRX) Chief R&D Officer receives large stock option and RSU inducement grants, https://www.stocktitan.net/sec-filings/BCRX/form-4-biocryst-pharmaceuticals-inc-insider-trading-activity-e573a0e7479a.html
56. BioCryst Pharmaceuticals (BCRX) Stock Forecast and Price Target 2026 - MarketBeat, https://www.marketbeat.com/stocks/NASDAQ/BCRX/forecast/
57. BioCryst to Report First Quarter 2026 Financial Results on May 6 - Stock Titan, https://www.stocktitan.net/news/BCRX/bio-cryst-to-report-first-quarter-2026-financial-results-on-may-uyiulfrskie8.html
58. BioCryst Pharmaceuticals Stock Surges 11% on HAE Expansion: Here's Where the Stock Could Be Headed in 2026 | TIKR.com, https://www.tikr.com/blog/biocryst-pharmaceuticals-stock-surges-11-on-hae-expansion-heres-where-the-stock-could-be-headed-in-2026
59. BCRX Technical Analysis, RSI and Moving Averages - Investing.com, https://www.investing.com/equities/biocryst-pharmaceuticals-technical
60. Financial Profile | BioCryst Pharmaceuticals, Inc., https://ir.biocryst.com/financial-information/key-ratios